In September 2004 the APPROVe (Adenomatous Polyp Prevention on Vioxx) trial was stopped early due to concerns about increased cardiovascular mortality in patients taking the drug. An analysis of the long-term outcomes of the patients in the trial has now been published in the Lancet. […]